Myriad Genetics, Inc.
|$2.5 B||Market Cap|
|3.4%||EBIT / EV|
|5.2%||FCF / EV|
|-0.2%||3yr Avg Revenue Growth|
Business Model Diligence
We do not yet have Business Model Diligence for this stock.
|The EBIT / Enterprise Value of 3.4% ranks as Below Average.|
|The Free Cash Flow / Enterprise Value of 5.2% ranks as Above Average.|
|The Return on Invested Capital Value of 9.2% ranks as Average.|
|The Cash Return on Capital Value of 14.2% ranks as Above Average.|
|The 3 Year Average Revenue Growth Value of -0.2% ranks as Below Average.|
|Near-term Financial Health appears to be Very Good. The Current Ratio is 2.34.|
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through two segments: Diagnostics and Other. The Diagnostics segment engages in the provision of testing that is designed to assess the risk for developing disease later in life of the patient, identify the likelihood of responding to drug therapy and guide the dosing to ensure optimal treatment, or assess a the disease progression and disease recurrence of the patient. The Other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients. The company was founded by Walter A. Gilbert, Mark H. Skolnick and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake, UT.
|Valvoline Inc. (VVV)|
|Procter & Gamble Company (PG)|
|McDonald's Corporation (MCD)|
|Fiat Chrysler Automobiles N.V. (FCAU)|
|Baozun Inc Sponsored ADR Class A (BZUN)|
|Vector Group Ltd. (VGR)|
|New Stocks Added!|